| Identification | Back Directory | [Name]
BOC-ORN-OH | [CAS]
21887-64-9 | [Synonyms]
BOC-ORN-OH
BOC-L-ORN-OH
BOC-ORNITHINE
BOC-L-ORNITHINE
N2-Boc-L-ornithine
Nα-Boc-L-Ornithine
BOC-ORN-OH USP/EP/BP
N^a-Boc-L-ornithine, 95%
N-.ALPHA.-BOC-L-ORNITHINE
BOC-ORN-OH;BOC--L-ORNITHINE
(Tert-Butoxy)Carbonyl Orn-OH
Nα-Boc-L-ornithine≥ 99% (HPLC)
N-(tert-butoxycarbonyl)-L-ornithine
N-ALPHA-T-BUTOXYCARBONYL-L-ORNITHINE
L-5-AMINO-2-N-BOC-AMINO-PENTANOIC ACID
N-ALPHA-T-BUTYLOXYCARBONYL-L-ORNITHINE
N-Alpha-(Tert-Butoxycarbonyl)-L-Ornithine
N-ALPHA-TERT-BUTYLOXYCARBONYL-L-ORNITHINE
L-Ornithine, N2-[(1,1-dimethylethoxy)carbonyl]-
L-5-AMINO-2-TERT-BUTOXYCARBONYLAMINO-PENTANOIC ACID
(S)-5-AMINO-2-TERT-BUTOXYCARBONYLAMINO-PENTANOIC ACID
(2S)-5-amino-2-{[(tert-butoxy)carbonyl]amino}pentanoic acid
(2S)-5-amino-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoicaci
(2S)-5-amino-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoic acid | [Molecular Formula]
C10H20N2O4 | [MDL Number]
MFCD00076970 | [MOL File]
21887-64-9.mol | [Molecular Weight]
232.28 |
| Chemical Properties | Back Directory | [Melting point ]
207-208℃ | [Boiling point ]
398.9±37.0 °C(Predicted) | [density ]
1.135±0.06 g/cm3(Predicted) | [storage temp. ]
Store at RT. | [solubility ]
Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | [form ]
Powder | [pka]
3.85±0.21(Predicted) | [color ]
White | [Optical Rotation]
[α]/D +24.0±2.0°, c = 1 in methanol | [BRN ]
4313353 | [Major Application]
peptide synthesis | [InChI]
1S/C10H20N2O4/c1-10(2,3)16-9(15)12-7(8(13)14)5-4-6-11/h7H,4-6,11H2,1-3H3,(H,12,15)(H,13,14)/t7-/m0/s1 | [InChIKey]
AMPVNPYPOOQUJF-ZETCQYMHSA-N | [SMILES]
NCCC[C@H](NC(OC(C)(C)C)=O)C(O)=O |
| Hazard Information | Back Directory | [Chemical Properties]
White to off-white powder | [Uses]
Nα-Boc-L-Ornithine, is a boc-protected analogue of L-Orthinine (O695550), a non essential amino acid and intermediate in arginine biosynthesis. It can be used in the enzymatic preparation of N-BOC-5-hydroxy-L-proline, and N-Cbz-5-hydroxy-L-proline, which are alternative key intermediates for the synthesis of Saxagliptin (S143500), used for the treatment of type II diabetes mellitus. | [reaction suitability]
reaction type: Boc solid-phase peptide synthesis |
|
|